Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Pharma-Bio Serv (PBSV) Cash & Equivalents (2016 - 2026)

Pharma-Bio Serv (PBSV) has disclosed Cash & Equivalents for 15 consecutive years, with $3.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Equivalents fell 50.07% year-over-year to $3.4 million, compared with a TTM value of $3.4 million through Oct 2025, down 50.07%, and an annual FY2025 reading of $3.4 million, down 50.07% over the prior year.
  • Cash & Equivalents was $3.4 million for Q4 2025 at Pharma-Bio Serv, down from $4.0 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $19.0 million in Q1 2021 and bottomed at $2.1 million in Q2 2025.
  • Average Cash & Equivalents over 5 years is $9.7 million, with a median of $7.7 million recorded in 2023.
  • The sharpest move saw Cash & Equivalents tumbled 79.85% in 2023, then soared 127.22% in 2024.
  • Year by year, Cash & Equivalents stood at $17.5 million in 2021, then fell by 17.21% to $14.5 million in 2022, then fell by 27.77% to $10.4 million in 2023, then plummeted by 35.22% to $6.8 million in 2024, then tumbled by 50.07% to $3.4 million in 2025.
  • Business Quant data shows Cash & Equivalents for PBSV at $3.4 million in Q4 2025, $4.0 million in Q3 2025, and $2.1 million in Q2 2025.